Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.
Oleg Demin Jr, Senior Modeler at Institute for Systems Biology Moscow will present two posters on application of QSP modelling in HCV therapeutic area.
Poster entitled "Prediction of Treatment Efficacy of Direct Antiviral Agent Combinations in Chronic Hepatitis C Patients Using Quantitative Systems Pharmacology Modeling Approach" on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster will demonstrate predictions of results of ongoing clinical trials of direct antiviral agents combinations for chronic hepatitis C patients with genotype 1. QSP model predicts primary endpoint SVR12 quantifying percent of patients with undetectable hepatitis C virus during 12 weeks after treatment completion. Poster ID is M45.
Poster entitled “Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach" on Tuesday, October 25th, 2016 at 7:30am to 9:00am. The poster will demonstrate how QSP model can describe suppression of immune response by hepatitis C virus. The model was applied to predict and explore results of treatment of chronic hepatits C patients with PD-1 inhibitor nivolumab. Poster ID is T56.
Institute for Systems Biology Moscow, Ltd. (www.insysbio.ru) is a leading R&D company providing services for mathematical modeling in drug research and development. ISBM is one of the pioneers in quantitative system pharmacology (QSP) modeling and simulation services and has been working on the market for more than 10 years. The company’s aim is to assist right decisions on the critical stages of drug research and development. ISBM team continuously improves methods and tools for biological modeling. Moreover, company works with students and postgraduates forming professional community of QSP-modelers. Company has published a lot of scientific studies, and has presented at major international conferences of the field. The ISBM innovative approach has become an integral part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharma industry.
Media contact:
Maria Maximova, media@insysbio.ru
| ← | October 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
1.
04 Oct 2024 16:13
InSysBio to participate in SITC 2024
InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Oct 2024 19:36
InSysBio to take part in "An Introduction to QSP" event
InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
|
31
| |||
Thank you for your message! We will get back to you shortly.
